Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer (NCT07091526) | Clinical Trial Compass
RecruitingNot Applicable
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
China168 participantsStarted 2025-07-29
Plain-language summary
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with pathologically confirmed pancreatic cancer (primary)
* Patients who underwent Radical resection of pancreatic cancer(Pancreaticoduodenectomy or Distal pancreatectomy)
* The postoperative survival time was at least 6 weeks
Exclusion Criteria:
* No surgery was performed, or only palliative surgery/ biopsy was performed
* Patients who underwent emergency hemodialysis or plasma exchange after surgery
* History of gout or long-term urate-lowering therapy, such as allopurinol
* Patients are missing follow-up data
* Hydrochlorothiazide and furosemide were used
* Chronic kidney disease
* Oncolytic syndrome
* Hemolytic anemia
* Lead poisoning
* Hyperparathyroidism
* Hypothyroidism
* A tyrosinase inhibitor was used
* Patients with nonpancreatic primary tumors
* Pregnant or postpartum women.
What they're measuring
1
Overall survival
Timeframe: 3-5 years
Trial details
NCT IDNCT07091526
SponsorHepatopancreatobiliary Surgery Institute of Gansu Province